3p-C-NETA: A Versatile Theranostic Chelator Platform Enabling Al18F- and 177Lu-Labeled SSTR2-Targeted Radioligands
Pharmaceutics · 02.11.2026 · 18 (11) · 1414
DOI: 10.3390/pharmaceutics18111414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 02.11.2026. Verfasst von Ward Storms und 9 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek (FWO)—Vlaanderen, FWO medium infrastructure grant, Research Foundation—Flanders.
Abstract (Originalsprache)
Background/Objectives: The FDA and EMA approvals of the theranostic radiopharmaceuticals [68Ga]Ga-/[177Lu]Lu-DOTA-TATE represent milestones in SSTR2-targeted radioligand development. The use of a single precursor for both diagnostic and therapeutic applications facilitates the development of matched theranostic agents. However, the DOTA chelator is not compatible with fluorine-18 (Al18F) labeling, which offers advantages in terms of imaging quality and clinical logistics. Here, we evaluated 3p-C-NETA-TATE, a precursor capable of incorporating either Al18F or lutetium-177, building on previous work establishing 3p-C-NETA as a versatile theranostic chelator platform.
Methods
The precursor 3p-C-NETA-TATE was labeled with Al18F or lutetium-177, and both compounds were evaluated in a preclinical setting. Both radioligands were assessed in vitro (binding affinity) and ex vivo (biodistribution) to determine their equivalent biological behavior. [177Lu]Lu-3p-C-NETA-TATE was compared with [177Lu]Lu-DOTA-TATE in terms of labeling efficiency, stability and cytotoxicity. Additionally, [18F]AlF-3p-C-NETA-TATE was used in a PET imaging study with tumor-bearing mice. Results: [177Lu]Lu-3p-C-NETA-TATE was obtained in quantitative radiolabeling yields (>95%) at a lower temperature and precursor concentration compared with [177Lu]Lu-DOTA-TATE, albeit with reduced stability in serum. In vitro, [177Lu]Lu-3p-C-NETA-TATE demonstrated comparable or improved characteristics. Both in vitro affinity experiments and ex vivo biodistribution studies indicated a similar biological profile for [18F]AlF-/[177Lu]Lu-3p-C-NETA-TATE.
Conclusions
This study demonstrates the theranostic potential of the 3p-C-NETA platform using TATE as a model targeting vector. The ability to support both Al18F and lutetium-177 labeling, combined with the comparable biological behavior of the resulting radioligands, highlights its potential as a versatile platform for the development of next-generation diagnostic and therapeutic radiopharmaceuticals.
Förderung
- Fonds Wetenschappelijk Onderzoek (FWO)—Vlaanderen
- FWO medium infrastructure grant
- Research Foundation—Flanders
- Neuroendocrine Tumor Research Foundation
Zitieren
APA
Storms, W., Ahenkorah, S., Ramdhani, D., Deroose, C. M., Cardinaels, T., Bormans, G., Watabe, H., Ooms, M., Kleynhans, J., & Cleeren, F. (2026). 3p-C-NETA: A Versatile Theranostic Chelator Platform Enabling Al18F- and 177Lu-Labeled SSTR2-Targeted Radioligands. Pharmaceutics, 18(11), 1414. https://doi.org/10.3390/pharmaceutics18111414
Vancouver
Storms W, Ahenkorah S, Ramdhani D, Deroose CM, Cardinaels T, Bormans G, et al. 3p-C-NETA: A Versatile Theranostic Chelator Platform Enabling Al18F- and 177Lu-Labeled SSTR2-Targeted Radioligands. Pharmaceutics. 2026;18(11):1414. doi:10.3390/pharmaceutics18111414
BibTeX
@article{Storms2026,
author = {Storms, Ward and Ahenkorah, Stephen and Ramdhani, Danni and Deroose, Christophe M. and Cardinaels, Thomas and Bormans, Guy and Watabe, Hiroshi and Ooms, Maarten and Kleynhans, Janke and Cleeren, Frederik},
title = {3p-C-NETA: A Versatile Theranostic Chelator Platform Enabling Al18F- and 177Lu-Labeled SSTR2-Targeted Radioligands},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1414},
doi = {10.3390/pharmaceutics18111414}
}
EUVIMED